These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 38907858)

  • 1. Combination of tumor antigen drainage and immune activation to promote a cancer-immunity cycle against glioblastoma.
    Xu H; Zhao X; Luo J
    Cell Mol Life Sci; 2024 Jun; 81(1):275. PubMed ID: 38907858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.
    Song E; Mao T; Dong H; Boisserand LSB; Antila S; Bosenberg M; Alitalo K; Thomas JL; Iwasaki A
    Nature; 2020 Jan; 577(7792):689-694. PubMed ID: 31942068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
    Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
    ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.
    Curtin JF; King GD; Candolfi M; Greeno RB; Kroeger KM; Lowenstein PR; Castro MG
    Curr Top Med Chem; 2005; 5(12):1151-70. PubMed ID: 16248789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma.
    van de Walle T; Vaccaro A; Ramachandran M; Pietilä I; Essand M; Dimberg A
    Front Immunol; 2021; 12():724739. PubMed ID: 34539661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
    Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
    Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for glioblastoma: the promise of combination strategies.
    Bausart M; Préat V; Malfanti A
    J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.